2LS.F SILOAM INTL HOS. RP 125
- Market cap
- EUR 961M
- P/E
- -
- P/B
- 2.05x
- ROE
- 11.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2LS.F undervalued?
Graham numberThe Graham number of SILOAM INTL HOS. RP 125 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SILOAM INTL HOS. RP 125 fundamental analysis
No fundamental analysis for SILOAM INTL HOS. RP 125 yet.
SILOAM INTL HOS. RP 125 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SILOAM INTL HOS. RP 125
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it off…
Full company profileSILOAM INTL HOS. RP 125 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SILOAM INTL HOS. RP 125 annual financial statements (IDR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 9.38T | 9.52T | 11.2T | 12.2T | 12.8T | 14.0T |
| Gross Profit | 3.62T | 3.53T | 4.46T | 4.86T | 4.95T | 5.39T |
| Operating Income | 1.14T | 1.11T | 1.78T | 1.83T | 1.75T | 1.99T |
| EBITDA | - | 1.82T | 2.53T | 2.28T | 2.70T | 2.96T |
| Net Income | 674B | 696B | 1.21T | 902B | 1.11T | 1.24T |
| EPS | 52 | 54 | 93 | 69 | 86 | 95 |
| Balance Sheet | ||||||
| Total Assets | 9.30T | 9.67T | 11.0T | 14.2T | 14.5T | 21.9T |
| Total Liabilities | 2.78T | 2.61T | 2.93T | 5.45T | 4.57T | 11.0T |
| Shareholders' Equity | 6.44T | 6.96T | 7.92T | 8.57T | 9.70T | 10.6T |
| Cash & Short-term Investments | 1.91T | 1.07T | 1.19T | 2.10T | 1.16T | 1.58T |
| Cash Flow | ||||||
| Capital Expenditure | 625B | 1.18T | 1.43T | 1.64T | 1.79T | 7.34T |
| Free Cash Flow | 1.41T | 505B | 671B | 693B | 669B | -5.18T |
| Ratios | ||||||
| ROE | 10.5% | 10.0% | 15.3% | 10.5% | 11.5% | 11.6% |
| ROA | 7.2% | 7.2% | 11.0% | 6.4% | 7.7% | 5.7% |
| Net Profit Margin | 7.2% | 7.3% | 10.8% | 7.4% | 8.7% | 8.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SILOAM INTL HOS. RP 125 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 10, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | IDR 260B | 20 | 28.8% |
| 2023 | IDR 255B | 20 | 21.1% |
| 2022 | IDR 250B | 19 | 35.9% |
| 2021 | IDR 225B | 17 | 33.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 8:1 on Apr 8, 2022.
Who owns SILOAM INTL HOS. RP 125
- Insiders 93.34%
- Institutions 0.81%
- Public & others 5.85%
- Shares outstanding 13.0B
- Free float 1.97B
SILOAM INTL HOS. RP 125 company profile
- Company name
- SILOAM INTL HOS. RP 125
- Ticker
- 2LS.F
- ISIN
- ID1000129208
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 14,872
- Fiscal year end
- December
- Address
- Gedung Fakultas Kedokteran Universitas Pelita Harapan (UPH), Tangerang, Indonesia, 15810
- Phone
- 62 21 2566 8000
- Website
- siloamhospitals.com
About SILOAM INTL HOS. RP 125
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardiology, neurology, nuclear medicine, obstetrics and gynecologist, occupational medicine, ophthalmology, orthopedic and traumatology, otorhinolaryngology, physical medicine and rehabilitation, pulmonology, radiation oncology, radiology, sports medicine, and urology. Further, it engages in trading, development, mining, agriculture, land transportation, printing, plantation, forestry, electrical, mechanical, engineering, construction, and real estate businesses; computer programming; software publishing and retail trading; provision of management consulting, retail, professional, and scientific and technical; web portal and/or digital platform business; workshops; leasing; wholesale trade; IT; and social services. The company was formerly known as PT Sentralindo Wirasta. PT Siloam International Hospitals Tbk was founded in 1996 and is headquartered in Tangerang, Indonesia. PT Siloam International Hospitals Tbk operates as a subsidiary of Sight Investment Company Pte. Limited.
SILOAM INTL HOS. RP 125 management
6- Mr. David UtamaPresident Director
- Dr. Mochtar RiadyFounder · born 1930
- Wily TjanderaInvestor Relations Manager
- Paulus SujonoHospital Chief Executive Officer
- Yuke Yolan GunawanHead of Internal Audit
- Ms. Ratih P. P. HadiwinotoCorporate Secretary · born 1989